Immunoproteasome Inhibitor (KZR-616) Desensitization and Maintenance Therapy in Highly Sensitized Non-Human Primates (WTC 2025) - Jul 30, 2025 - Abstract #OA35.7; Pres time: Aug 5, 2025; 05:26 PM - 05:33 PM; Location: Room 10; "*Purpose: Immunoproteasome inhibitors (IPI), selectively targeting hematopoietic cells, exhibit lower toxicity than conventional PIs. Desensitization with IPI therapy was well tolerated in highly sensitized rhesus monkeys. This study demonstrates that IPI-based desensitization effectively reduces DSA. While IPI alone did not extend graft survival, its combination with belatacept yielded prolonged graft survival."
Clinical • Antibody-mediated Rejection • CD4
|
|
A. Martinino; M. Tunbridge; J. Ladowski; D. Schiliró; I. Anwar; I. DeLaura; J. Yoon; Z. Li; K. Fung; M. Hu; M. Manook; N. Bazzi; K. Williams; A. Jackson; J. Kwun; S. Knechtle
|